Paul J. Clancy - 23 Mar 2026 Form 4 Insider Report for EXACT SCIENCES CORP (EXAS)

Reporting relationship: Director
Issuer ticker: EXAS
Reported as of: 23 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Mar 2026, 09:18:12 UTC
Prior SEC filing: 05 Jan 2026
Next SEC filing: 02 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Paul J. Clancy by Mark Busch, attorney-in- fact

Key filing fact

Paul J. Clancy filed Form 4 for EXACT SCIENCES CORP (EXAS) on 23 Mar 2026.

Key facts

This page summarizes Paul J. Clancy's Form 4 filing for EXACT SCIENCES CORP (EXAS).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 23 Mar 2026, 09:18.

Change

Previous filing in this sequence was filed on 05 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001409601 Primary reporting owner

Clancy Paul J

Relationship: Director
Address: C/O EXACT SCIENCES CORP., 5505 ENDEAVOR LANE, MADISON
Signature: /s/ Paul J. Clancy by Mark Busch, attorney-in- fact
Signature date: 23 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EXAS transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -20,640
Change %: -79%
Price
Shares after: 5,398
Date: 23 Mar 2026
Ownership: Direct
Footnotes: F1

EXAS transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -5,398
Change %: -100%
Price
Shares after: 0
Date: 23 Mar 2026
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Paul J. Clancy is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration").

Footnote F2

At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.